Related content

Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny

By Suda Kenichi  

Cancer and Metastasis Reviews, Vol. 31, Iss. 3-4, 2012-12 ,pp. : 807-814

Springer Publishing Company

Access to resources Recommend Favorite

Primary and Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer: An Update

By Ayoola Ayodele   Barochia Amit   Belani Kiran   Belani Chandra P.  

Cancer Investigation, Vol. 30, Iss. 5, 2012-05 ,pp. : 433-446

Informa Healthcare

Access to resources Recommend Favorite

Epidermal growth factor receptortyrosine kinase inhibitors for nonsmallcell lung cancer patients aged 80 years or older: A retrospective analysis

By  

Molecular and Clinical Oncology, Vol. 3, Iss. 2, 2015-01 ,pp. : 403-407

Science Publishers

Access to resources Recommend Favorite

Combined gefitinib and pemetrexed overcome the acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

By        

Molecular Medicine Reports, Vol. 10, Iss. 2, 2014-01 ,pp. : 931-938

Spandidos Publications

Access to resources Recommend Favorite

Alteration of the E-cadherin/β-Catenin Complex Predicts Poor Response to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI) Treatment

By Yoo Seol   Kim Yu   Kim Hyojin   Jin Yan   Sun Ping-Li   Jheon Sanghoon   Lee Jong   Chung Jin-Haeng  

Annals of Surgical Oncology, Vol. 20, Iss. 3, 2013-12 ,pp. : 545-552

Springer Publishing Company

Access to resources Recommend Favorite